大參林(603233.SH):擬與關聯方等共設參力科技、負責大健康創新總部中心獲取土地資源及相關建設等
格隆匯1月18日丨大參林(603233.SH)公佈,公司為打造大健康創新總部中心需要,並基於投資成本以及風險共擔等因素考慮,擬由子公司與關聯方參發投資、隆鵬科技、智尚物業以貨幣出資方式共同出資設立“廣州參力科技有限公司”(暫定名,以工商核定名稱為準,“參力科技”),並由參力科技負責大健康創新總部中心獲取土地資源及相關建設等事宜。參力科技擬註冊資本人民幣10億元,其中,公司通過全資子公司廣州珂芙尼貿易有限公司(“珂芙尼貿易”)持有61%股權,參發投資、隆鵬科技和智尚物業各持有13%股權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.